Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial
Locke J. Bryan, Carla Casulo, Pamela B. Allen, Scott E. Smith, Hatice Savas, Gary L. Dillehay, Reem Karmali, Barbara Pro, Kaitlyn L. Kane, Latifa A. Bazzi, Joan S. Chmiel, Brett A. Palmer, Jayesh Mehta, Leo I. Gordon, Jane N. Winter
Dive into the research topics of 'Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial'. Together they form a unique fingerprint.